Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 PP359 | DOI: 10.1530/boneabs.3.PP359

Osteoporosis: treatment

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Norbert Hassler, Sonja Gamsjaeger, Birgit Hofstetter, Wolfgang Brozek, Barbara Misof, Paul Roschger, Klaus Klaushofer & Eleftherios Paschalis

25 views


First Medical Department, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, Hanusch Hospital, Vienna, Austria.


Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by Raman microspectroscopic analysis of iliac crest biopsies from postmenopausal osteoporosis patients that were either on 5-year ALN therapy followed by another 5 years of placebo (PLC) (n=14), or on 5 mg/day ALN for 10 years (n=10), or 10 : mg/day ALN for 10 years (n=6). The parameters monitored and expressed as a function of tissue age defined on basis of double tetracycline labels and geometrical centra of trabeculae were: i) the mineral : matrix ratio (MM), ii) the relative proteoglycan content (PG), iii) the relative lipids content (LPD), iv) the mineral maturity/crystallinity (MMC), and vi) the relative pyridinoline content (PYD). The results indicate that 10-year ALN use (both 5 and 10 mg/day) does not result in any detrimental changes compared to use for 5 years. The only differences were transient ones at bone forming surfaces, implying potential differences in bone matrix maturation that nevertheless did not result in differences of these values in mature tissue. These results indicate that as far as the parameters monitored are concerned, 10 years ALN use does not change the bone material quality at the examined tissue ages compared to 5-year use. Additionally, it is suggested that prolonged bisphosphonate use when accompanied with residual bone turnover may not be responsible by itself for an impairment in bone material quality contributing to adverse conditions such as atypical femoral fractures.

Volume 3

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.